Controlling blood pressure to reduce heart risks during breast cancer treatment
Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial
['FUNDING_R37'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11094035
This study is looking at how closely managing blood pressure can help protect the hearts of breast cancer patients who are receiving certain treatments, making sure they stay healthy while fighting cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11094035 on ClinicalTrials.gov |
What this research studies
This research investigates how intensive blood pressure control can help reduce cardiovascular risks in breast cancer patients undergoing treatment. It focuses on patients who may experience heart-related side effects from cancer therapies, particularly those using anthracyclines and HER2-targeted agents. By monitoring and managing blood pressure more aggressively, the study aims to prevent heart damage and improve overall treatment outcomes. The approach includes careful tracking of blood pressure and adjusting medications as needed to ensure optimal heart health during cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients who have hypertension and are receiving cardiotoxic cancer therapies.
Not a fit: Patients who do not have hypertension or are not undergoing cardiotoxic cancer treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the risk of heart complications for breast cancer patients undergoing treatment.
How similar studies have performed: Previous trials have shown that intensive blood pressure control can reduce cardiovascular risks, but this specific approach in cancer patients is novel and has not been extensively tested.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YU, ANTHONY FRANCIS — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: YU, ANTHONY FRANCIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy